Active Ingredient History
Live attenuated influenza vaccine (LAIV) is a type of influenza vaccine in the form of a nasal spray that is recommended for the prevention of influenza. In June 2016, the Centers for Disease Control and Prevention (CDC) stopped recommending the use of LAIV as its effectiveness had appeared to have decreased between 2013 and 2016, but this recommendation was reversed in February 2018, for the 2018-2019 influenza season. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Asthma (Phase 4)
Chronic Disease (Phase 3)
Egg Hypersensitivity (Phase 4)
Healthy Volunteers (Phase 4)
HIV Infections (Phase 2)
Immunity (Phase 4)
Immunization (Phase 1)
Influenza A virus (Phase 1)
Influenza A Virus, H1N1 Subtype (Phase 4)
Influenza, Human (Phase 4)
Influenza in Birds (Phase 1)
Influenza Vaccines (Phase 4)
Neoplasms (Phase 1)
Pneumonia (Phase 4)
Pulmonary Disease, Chronic Obstructive (Early Phase 1)
Respiratory Sounds (Phase 4)
Respiratory Tract Infections (Phase 4)
Vaccines (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue